$1.95
4.8%
Price vs. AI Score (Last 150 days)
Data gathered: December 1
Data gathered: December 1
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | 1 0% |
|
| Sentiment | 97 3.2% |
|
| Webpage traffic | 78,000 78.4% |
|
| Employee Rating | 81 0% |
|
| Linkedin Employees | 318 N/A |
|
| 4chan Mentions | 0% |
|
| Facebook Engagement | 5 -66.7% |
|
| Facebook followers | 2,555 0% |
|
| Stocktwits Mentions | 24 -36.8% |
|
| Stocktwits Subscribers | 673 1.5% |
|
| Twitter Followers | 379 0% |
|
| News Mentions | 0% |
|
| Reddit Mentions | 0% |
|
| Business outlook | 100 0% |
|
In the news
FDA Accepts Arcutis Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6November 29 - Finnhub |
|
 |
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6November 28 - Yahoo |
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Axsome Therapeutics (AXSM) and Cytokinetics (CYTK)November 28 - TipRanks |
|
Arcutis Biotherapeutics announces U.S. FDA accepted sNDA for roflumilast creamNovember 28 - Thefly.com |
|
Arcutis lead product undergoes FDA review for label expansionNovember 28 - Seeking Alpha |
|
 |
Morgan Stanley Trims Arcutis Biotherapeutics (NASDAQ:ARQT) Target Price to $10.00November 17 - ETF Daily News |
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
| Price | $1.95 |
| Target Price | Sign up |
| Market Cap | $179M |
| Dividend Yield | 0 |
| Industry | Biotechnology |
Similar companies
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 31M | 236M | -205M | -45M | 154M |
| Q2 '23 | 5.2M | 234M | -229M | -71M | 124M |
| Q1 '23 | 2.8M | 43M | -47M | -80M | -73M |
| Q4 '22 | 3M | 40M | -44M | -72M | -65M |
| Q3 '22 | 730,000 | 35M | -40M | -108M | -103M |
Insider Transactions
| Matsuda Masaru filed to sell 46,634 shares at $2. November 21 '23 |
| Topper James N filed to buy 8,764,232 shares at $2.5. October 26 '23 |
| Burnett Patrick filed to sell 58,357 shares at $7. August 22 '23 |
| Matsuda Masaru filed to sell 42,146 shares at $7.8. June 2 '23 |
| Welgus Howard G. filed to sell 165,825 shares at $14. April 18 '23 |
Read more about Arcutis Biotherapeutics and their earnings, price prediction, job posts, sentiment, webpage traffic, employee rating, linkedin employees, 4chan mentions, facebook engagement, facebook followers, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, reddit mentions, business outlook.